|Bid||1.0000 x 900|
|Ask||1.7200 x 1000|
|Day's range||1.6500 - 1.7300|
|52-week range||1.1500 - 11.4100|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||10 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.00|
Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and Banner Health today announced that Sera's PreTRM® Test will be available to Banner – University Family Care/ AHCCCS Complete Care (B – UFC/ACC) members. The PreTRM® Test is the only broadly clinically validated, commercially available blood test that provides an early, individual risk assessment for sp
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Good afternoon and welcome to the Sera Prognostics' conference call to review the second quarter fiscal year 2022 results. At the close of the market today, Sera Prognostics released its financial results for the quarter ended June 30, 2022. Presenting for the company today will be Greg Critchfield, chairman, president, and CEO; and Jay Moyes, our CFO.